Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Pfizer Inc. (PFE : NYSE)
 
 • Company Description   
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.

Number of Employees: 79,000

 
 • Price / Volume Information   
Yesterday's Closing Price: $52.47 Daily Weekly Monthly
20 Day Moving Average: 26,630,814 shares
Shares Outstanding: 5,610.90 (millions)
Market Capitalization: $294,403.72 (millions)
Beta: 0.76
52 Week High: $61.71
52 Week Low: $38.48
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 9.02% 19.37%
12 Week 9.95% 23.58%
Year To Date -11.14% 8.55%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
235 EAST 42ND STREET
-
NEW YORK,NY 10017
USA
ph: 212-733-2323
fax: 302-655-5049
None http://www.pfizer.com
 
 • General Corporate Information   
Officers
Albert Bourla - Chief Executive Officer and Chairman
Frank A. D'Amelio - Chief Financial Officer and Executive Vice Preside
Jennifer B. Damico - Senior Vice President and Controller
Ronald E. Blaylock - Director
Susan Desmond-Hellmann - Director

Peer Information
Pfizer Inc. (AGN.)
Pfizer Inc. (ABBV)
Pfizer Inc. (NVO)
Pfizer Inc. (LLY)
Pfizer Inc. (RHHBY)
Pfizer Inc. (JNJ)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: Large Cap Pharma
Sector: Medical
CUSIP: 717081103
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 07/27/22
Share - Related Items
Shares Outstanding: 5,610.90
Most Recent Split Date: 7.00 (3.00:1)
Beta: 0.76
Market Capitalization: $294,403.72 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 3.05%
Current Fiscal Quarter EPS Consensus Estimate: $2.02 Indicated Annual Dividend: $1.60
Current Fiscal Year EPS Consensus Estimate: $6.63 Payout Ratio: 0.31
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: -0.17
Estmated Long-Term EPS Growth Rate: 12.47% Last Dividend Paid: 05/12/2022 - $0.40
Next EPS Report Date: 07/27/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 7.91
Trailing 12 Months: 10.27
PEG Ratio: 0.63
Price Ratios
Price/Book: 3.58
Price/Cash Flow: 9.68
Price / Sales: 3.18
EPS Growth
vs. Year Ago Period: 74.19%
vs. Previous Quarter: 50.00%
Sales Growth
vs. Year Ago Period: 75.98%
vs. Previous Quarter: 7.65%
ROE
03/31/22 - 38.29
12/31/21 - 34.53
09/30/21 - 30.70
ROA
03/31/22 - 16.42
12/31/21 - 14.65
09/30/21 - 12.92
Current Ratio
03/31/22 - 1.39
12/31/21 - 1.40
09/30/21 - 1.39
Quick Ratio
03/31/22 - 1.13
12/31/21 - 1.19
09/30/21 - 1.18
Operating Margin
03/31/22 - 31.69
12/31/21 - 30.99
09/30/21 - 30.84
Net Margin
03/31/22 - 26.97
12/31/21 - 26.97
09/30/21 - 27.66
Pre-Tax Margin
03/31/22 - 29.89
12/31/21 - 29.91
09/30/21 - 29.91
Book Value
03/31/22 - 14.64
12/31/21 - 13.80
09/30/21 - 13.55
Inventory Turnover
03/31/22 - 4.00
12/31/21 - 3.51
09/30/21 - 2.80
Debt-to-Equity
03/31/22 - 0.43
12/31/21 - 0.47
09/30/21 - 0.48
Debt-to-Capital
03/31/22 - 30.13
12/31/21 - 31.85
09/30/21 - 32.30
 

Powered by Zacks Investment Research ©